Table 1.
Patients characteristics and univariate analysis of prognostic factors for survival
|
Characteristic |
LRFS |
OS |
|||||
|---|---|---|---|---|---|---|---|
| n | 5-year (%) | 10-year (%) | p | 5-year (%) | 10-year (%) | p | |
| Age (y) |
|
|
|
|
|
|
|
| ≤ 35 |
134 |
76.0 |
70.4 |
0.020* |
74.4 |
66.4 |
0.113 |
| > 35 |
934 |
85.4 |
82.7 |
|
80.5 |
67.4 |
|
| Menopausal status |
|
|
|
|
|
|
|
| Premenopausal |
697 |
81.8 |
79.3 |
0.026* |
80.3 |
68.9 |
0.589 |
| Postmenopausal |
371 |
89.0 |
85.1 |
|
78.7 |
63.4 |
|
| Tumor size |
|
|
|
|
|
|
|
| T1-2 |
916 |
86.4 |
83.6 |
<0.001* |
81.8 |
70.9 |
<0.001* |
| T3-4 |
97 |
70.2 |
70.2 |
|
61.2 |
36.1 |
|
| Unknown |
55 |
|
|
|
|
|
|
| No of positive lymph nodes |
|
|
|
|
|
|
|
| pN1 (1–3) |
780 |
88.7 |
86.1 |
<0.001* |
86.1 |
77.7 |
<0.001* |
| pN2 (4–9) |
183 |
77.0 |
73.0 |
|
69.7 |
51.0 |
|
| pN3 (≥ 10) |
105 |
60.6 |
53.8 |
|
49.9 |
20.8 |
|
| Lymph node ratio |
|
|
|
|
|
|
|
| < 0.20 |
690 |
90.2 |
87.7 |
<0.001* |
87.1 |
78.6 |
<0.001* |
| 0.21-0.65 |
269 |
78.6 |
74.9 |
|
75.1 |
60.9 |
|
| > 0.65 |
109 |
57.5 |
52.3 |
|
44.3 |
21.5 |
|
| ER status |
|
|
|
|
|
|
|
| Positive |
599 |
85.9 |
84.4 |
0.008* |
83.9 |
69.0 |
<0.001* |
| Negative |
393 |
81.0 |
76.7 |
|
72.2 |
64.2 |
|
| Unknown |
76 |
|
|
|
|
|
|
| PR status |
|
|
|
|
|
|
|
| Positive |
652 |
85.9 |
83.4 |
0.008* |
83.0 |
72.6 |
<0.001* |
| Negative |
340 |
80.3 |
77.6 |
|
72.3 |
57.0 |
|
| Unknown |
76 |
|
|
|
|
|
|
| HER-2-neu status |
|
|
|
|
|
|
|
| Positive |
321 |
81.8 |
79.7 |
0.077 |
75.6 |
66.2 |
0.026* |
| Negative |
585 |
85.5 |
82.0 |
|
82.7 |
71.2 |
|
| Unknown |
162 |
|
|
|
|
|
|
| Chemotherapy regimen |
|
|
|
|
|
|
|
| CMF |
142 |
82.1 |
79.6 |
0.332 |
76.0 |
60.1 |
0.069 |
| Anthracycline and/or taxane |
850 |
84.9 |
81.9 |
|
81.5 |
71.0 |
|
| None/unknown |
76 |
|
|
|
|
|
|
| Hormone therapy |
|
|
|
|
|
|
|
| Yes |
718 |
85.7 |
82.5 |
0.032* |
83.7 |
70.5 |
<0.001* |
| None | 350 | 81.4 | 78.8 | 71.2 | 60.4 | ||
LRFS, Locoregional recurrence-free survival; OS, Overall survival; ER, Estrogen receptor; PR, Progesterone receptor; Her-2, Human epithelial growth factor receptor family 2; CMF, Cyclophosphamide, methotrexate, and 5-fluorouracil.
*p<0.05 indicates a significant difference.